Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 120 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depressive Episode Clear all
Completed Phase 1Phase 2 Interventional Results available

Treating Depression With Transcranial Direct Current Stimulation (tDCS)

NCT00481988
View directory record Official record
Conditions
Depression
Interventions
transcranial direct current stimulation, iomed phoresor transcranial direct current stimulation
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 21, 2026, 4:29 AM EDT
Completed No phase listed Observational

Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)

NCT05708222
View directory record Official record
Conditions
Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major, Depression Mild
Interventions
MEB-001
Device
Lead sponsor
Medibio Limited
Industry
Eligibility
22 Years to 75 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Bradenton, Florida • Blaine, Minnesota • Plymouth, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

NCT00629551
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
saredutant (SR48968), paroxetine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 21, 2026, 4:29 AM EDT
Active, not recruiting Phase 2 Interventional

Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression

NCT03349528
View directory record Official record
Conditions
Bipolar Depression
Interventions
Probiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

NCT00531622
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
saredutant (SR48968), escitalopram, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 21, 2026, 4:29 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

NCT07220460
View directory record Official record
Conditions
Bipolar I or II Disorder
Interventions
ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Phoenix, Arizona • Anaheim, California • Colton, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

NCT03249376
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lumateperone, Placebo
Drug · Other
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Sherman Oaks, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 21, 2026, 4:29 AM EDT
Recruiting Phase 2 Interventional

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

NCT07494305
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
LB-102, Placebo
Drug · Other
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

NCT00252356
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SR58611A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional

Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression

NCT04469322
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major, Depression, Bipolar, Depressive Episode
Interventions
Mental Health DNA Insight Test (Pathway Genomics), Sham Test
Diagnostic Test
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 21, 2026, 4:29 AM EDT
Terminated Phase 2 Interventional Results available

NeoSync TMS Treatment for Bipolar I Depression

NCT02839798
View directory record Official record
Conditions
Major Depressive Episode, Bipolar Depression, Bipolar Disorder, Mood Disorders
Interventions
NEST (NeoSync EEG Synchronized TMS)
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder

NCT03716869
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Episode
Interventions
Universal Screening Arm
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
12,909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 1Phase 2 Interventional

Personalized Ultrasonic Brain Stimulation for Depression

NCT05301036
View directory record Official record
Conditions
Major Depressive Episode
Interventions
Diadem prototype
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Recruiting Phase 3 Interventional

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

NCT07775300
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

NCT00309699
View directory record Official record
Conditions
Bipolar Disorder, Mood Disorders
Interventions
Placebo, Quetiapine, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Cerritos, California • Garden Grove, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional

Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)

NCT01361815
View directory record Official record
Conditions
Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
Interventions
H-Coil Deep TMS in combination with SSRIs
Device
Lead sponsor
Brainsway
Industry
Eligibility
22 Years to 68 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Davis, California • Los Angeles, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 4 Interventional Results available

Tranylcypromine Treatment of Bipolar Depression

NCT01430455
View directory record Official record
Conditions
Bipolar Disorder I or II
Interventions
Tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Electroconvulsive Therapy Amplitude Titration

NCT04621786
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
Device
Lead sponsor
University of New Mexico
Other
Eligibility
50 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Self-guided Treatment for Adolescents Navigating Depression

NCT05462652
View directory record Official record
Conditions
Depressive Symptoms, Depression, Depressive Disorder, Depressive Episode
Interventions
Active Intervention
Device
Lead sponsor
Limbix Health, Inc.
Industry
Eligibility
13 Years to 21 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

NCT00186498
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
memantine, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for Suicidality in Bipolar Depression

NCT01944293
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Episode, Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

NCT00672620
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
38
States / cities
Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 21, 2026, 4:29 AM EDT